Yuming Zhao

Shenzhen, 518107, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications

Ultrasensitive Detection of Rare Mutations via Amplifying-Cleaving-Enriching in Acute Myeloid Leukemia.

Ultrasensitive Detection of Rare Mutations via Amplifying-Cleaving-Enriching in Acute Myeloid Leukemia.

Journal: Biomedicines
Published: August 20, 2025

Homoharringtonine and Gilteritinib Synergistically Induce Apoptosis and Suppress Viability in FLT3-ITD-Positive AML Cells.

Homoharringtonine and Gilteritinib Synergistically Induce Apoptosis and Suppress Viability in FLT3-ITD-Positive AML Cells.

Journal: Biomedicines
Published: August 14, 2025

A novel conditioning regimen involving haploid immune cell infusion combined with umbilical cord blood transplantation for the treatment of juvenile myelomonocytic leukemia.

A novel conditioning regimen involving haploid immune cell infusion combined with umbilical cord blood transplantation for the treatment of juvenile myelomonocytic leukemia.

Journal: European journal of pediatrics
Published: January 22, 2025

FLT3L-based drug conjugate effectively targets chemoresistant leukemia stem cells in acute myeloid leukemia.

FLT3L-based drug conjugate effectively targets chemoresistant leukemia stem cells in acute myeloid leukemia.

Journal: Cell reports. Medicine
Published: November 21, 2024

Progression and perspectives in disease modeling for Juvenile myelomonocytic leukemia.

Progression and perspectives in disease modeling for Juvenile myelomonocytic leukemia.

Journal: Medical oncology (Northwood, London, England)
Published: September 03, 2024

FLT3 inhibitors induce p53 instability, driven by STAT5/MDM2/p53 competitive interactions in acute myeloid leukemia.

FLT3 inhibitors induce p53 instability, driven by STAT5/MDM2/p53 competitive interactions in acute myeloid leukemia.

Journal: Cancer letters
Published: May 21, 2024

Targeting Glutamine Metabolism as an Attractive Therapeutic Strategy for Acute Myeloid Leukemia.

Targeting Glutamine Metabolism as an Attractive Therapeutic Strategy for Acute Myeloid Leukemia.

Journal: Current treatment options in oncology
Published: April 22, 2023

miR-221/222 induce instability of p53 By downregulating deubiquitinase YOD1 in acute myeloid leukemia.

miR-221/222 induce instability of p53 By downregulating deubiquitinase YOD1 in acute myeloid leukemia.

Journal: Cell death discovery
Published: April 12, 2023

Sunitinib selectively targets leukemogenic signaling of mutant SHP2 in juvenile myelomonocytic leukemia.

Sunitinib selectively targets leukemogenic signaling of mutant SHP2 in juvenile myelomonocytic leukemia.

Journal: Biochemical pharmacology
Published: February 23, 2023

Transcriptome analysis reveals effects of leukemogenic SHP2 mutations in biosynthesis of amino acids signaling.

Transcriptome analysis reveals effects of leukemogenic SHP2 mutations in biosynthesis of amino acids signaling.

Journal: Frontiers in oncology
Published: November 05, 2022

Leukemogenic SHP2 mutations lead to erythropoietin independency of HCD-57 cells: a novel model for preclinical research of SHP2-mutant JMML.

Leukemogenic SHP2 mutations lead to erythropoietin independency of HCD-57 cells: a novel model for preclinical research of SHP2-mutant JMML.

Journal: Experimental hematology & oncology
Published: October 29, 2022

The Molecular Mechanisms of Resistance to IDH Inhibitors in Acute Myeloid Leukemia.

The Molecular Mechanisms of Resistance to IDH Inhibitors in Acute Myeloid Leukemia.

Journal: Frontiers in oncology
Published: April 29, 2022
Showing 1-12 of 16

Last Updated: 09/26/2026